Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

GlaxoSmithKline UK
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 01/02/2012
SPC Zinacef

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 01/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   27-Jan-2012
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Section

Summary of change

6.3

 Shelf life extension from 2 years to 3 years

10.

Updated with new date of revision of text
Updated on 19/11/2008 and displayed until 01/02/2012
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   17-Nov-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.4 - Amendment to add renal impairment and the warning for overgrowth of non-susceptible organisms

Section 4.5 - Information added regarding interaction with oral contraceptives

Section 4.8 - Very rare adverse event of cutaneous vasculitis has been added

Section 10 - Added the date of approval
Updated on 16/05/2006 and displayed until 19/11/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 12/05/2006 and displayed until 16/05/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC:   03/05/06
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

For further information, please contact GlaxoSmithKline on +44 (0)800 221 441
Updated on 23/07/2003 and displayed until 12/05/2006
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 11/02/2003 and displayed until 23/07/2003
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
  • Change to section 8 - MA number
Updated on 30/05/2002 and displayed until 11/02/2003
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 20/08/2001 and displayed until 30/05/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 22/05/2002 and displayed until 20/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 18/10/2000 and displayed until 22/05/2002
Reasons for adding or updating:
  • No reasons supplied
Updated on 15/05/2000 and displayed until 18/10/2000
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 15/05/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  cefuroxime sodium